Recent progress in application of nanovaccines for enhancing mucosal immune responses

作     者：Guangsheng Du Ming Qin Xun Sun Guangsheng Du;Ming Qin;Xun Sun

作者机构：Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan ProvinceSichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial TechnologyWest China School of PharmacySichuan UniversityChengdu 610041China 

出 版 物：《药学学报:英文版》 (Acta Pharmaceutica Sinica B)

年 卷 期：2023年第13卷第6期

页      面：2334-2345页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by National Natural Science Foundation of China (Grant Nos. 81925036 & 82003684) China Postdoctoral Science Foundation Grant (2019M663534, China) the Key Research and Development Program of Science and Technology Department of Sichuan Province (No. 2020YFS0570, China) Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (CARS-SVDIP, China) the Fundamental Research Funds for the Central Universities Sichuan University Postdoctoral Interdisciplinary Innovation Fund 

主　　题：Mucosal vaccines Nanovaccines Cell targeting Adjuvants Infectious diseases Mucus adhesion and penetration Mucosal immune system M cells 

摘      要：Mucosal vaccines that stimulate both mucosal and systemic immune responses are desirable,as they could prevent the invading pathogens at their initial infection sites in a convenient and userfriendly way. Nanovaccines are receiving increasing attention for mucosal vaccination due to their merits in overcoming mucosal immune barriers and in enhancing immunogenicity of the encapsulated ***, we summarized several nanovaccine strategies that have been reported for enhancing mucosal immune responses, including designing nanovaccines that have superior mucoadhesion and mucus penetration capacity, designing nanovaccines with better targeting efficiency to M cells or antigen-presenting cells, and co-delivering adjuvants by using nanovaccines. The reported applications of mucosal nanovaccines were also briefly discussed, including prevention of infectious diseases, and treatment of tumors and autoimmune diseases. Future research progresses in mucosal nanovaccines may promote the clinical translation and application of mucosal vaccines.